Hypolipidaemic and antiplatelet agents

Bibliography

• VAN GAAL LF, ZHANG A, STEIJAERT MM, DE LEEUW IH: Human obesity: from lipid abnormalities to lipid oxidation. Intl Obes. (1995) 19(S3):S21–S26.
   Google Scholar
• MCCULLY KS: Homocysteine and vascular disease. Nat. Med. (1996) 2:386–389.
   PubMed Web of Science ®Google Scholar
• DUELL BE MALINOW MR: Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr. Opin Lipidol (1997) 8:28–34.
   PubMedGoogle Scholar
• GILES WH, CROFT JB, GREENLUND KJ, FORD ES, KITTNER SJ. Am. Heart J. (2000) 139:446–453.
   PubMedGoogle Scholar
• ROSS R: The patogenesis of atherosclerosis. In: Heart Diseas: A Taxtbook of Cardiovascular Medicine. Braurnvald E (Ed.) Saunders, Philadelphia, PA, USA (1988):1135–1152.
   Google Scholar
• SCHELL DW, MYERS JN: Regression of atherosclerosis: a review. Frog. Card. Drs. (1997) 39:483–496.
   PubMedGoogle Scholar
• BROWN BG, ZHAO X, SACCO DE, ALBERS JJ: Lipid lowering and plaque regression: New insight into prevention of plaque disruption and clinical events in coronary disease. Circulation (1993) 87:1781–1789.
   PubMed Web of Science ®Google Scholar
• BADIMON JJ, FUSTER V, BADIMON L: Role of high density lipoproteins in the regression of atherosclerosis. Circulation (1992) 86 (Suppl. III) :11–86–111–94.
   Google Scholar
• WILLNOW TE: The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. j Mol. Med. (1999) 77:306–315.
   PubMedGoogle Scholar
• ••Intersting review on the role of LDL inlipids.
   Google Scholar
• HUSSAIN MM, STRICKLAND DK, BAKILLAH A: The mammalian low-density lipoprotein receptor family. Ann. Rev Num. (1999) 19:141–172.
   PubMed Web of Science ®Google Scholar
• MULS E, KEMPEN K, VANSANT G, COBBAERT C, SARIS W: The effects of weight loss and apolipoprotein E polymorphism on on serum lipids, apolipoproteins Al and B, and Lp(a). Int. Obes. (1993) 17:711–716.
   PubMedGoogle Scholar
• BADIMON L, CHESEBRO JH, BADIMON JJ: Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving trombi. Circulation (1992) 86 (suppl. III):111–74–11183.
   Google Scholar
• HEINECKE JW: Cellular mechanisms for the oxidative modification of lipoproteins: implications for atherogenesis. Carom Artery Dis. (1994) 5:205–210.
   PubMed Web of Science ®Google Scholar
• ZHANG A, VERTOMMEN J, VAN GAAL L et al: A rapid and simple method for measuring the cusceptibility of low-density-lipoprotein to copper catalysed oxidation. Chim. Acta (1994) 227:159–173.
   PubMed Web of Science ®Google Scholar
• STEINBERG D, PARTHASARATHY S, CAREW TE, KHO JC, WITZUM JL: Beyond cholesterol. Modifications of low-density-lipoprotein that increase its atherogenicity. New Engl. I Med. (1989) 320:915–924.
   Google Scholar
• MILLER GJ: Lipoproteins and the haemostatic system in atherothrobotic disorders. Baillieres Best Pract. Res. Clin. Haematol (1999) 12:555–75.
   PubMedGoogle Scholar
• ZHAO SP, XU DY: Oxidized lipoprotei(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb. Res. (2000) 100:501–510.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Changing concepts of atherogenesis. I Int. Med. (2000) 247:349–358.
   PubMed Web of Science ®Google Scholar
• ORFORD JL, SELWYN AP GANZ P, POMPA JJ, ROGERS C: The comparative pathobiology of atherosclerosis and restenosis. Am. j. Cordial. (2000) 86(Suppl.):6H–11H
   Google Scholar
• LIBBY P: Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin. Cordial. (2000) 23 (suppl 6):VI–3–7
   Google Scholar
• ALAUPOVIC P, MACK WJ, KNIGHT-GIBBSON C, HODIS N: The role of tridlyceride rich lipoprotein in families in the progression of atherosclerotic ;esions as determined by sequential coronary angiography from controlled clinical trials. Arteriscler. Thromb. Vase. Biol. (1997) 17:715–722.
   PubMed Web of Science ®Google Scholar
• HODIS HN, MACK WJ: Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur. Heart J. (1998) 19 (Suppl A):A40–A44.
   Google Scholar
• NOULA C, BONZOM P, BROWN A, GIBBONS WA, MARTIN J, NICOLAOU A: 1-HNMR lipid profiles of human blood platelets: links with coronary artery disease. Biochim. Biophys. Acta. (2000) 1487:15–23.
   PubMedGoogle Scholar
• LARSSON B, SVARSODD K, WELIN L, WILMHELMSEN L, BJORNTORP P, TIBBLIN G: Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br. J. Med. (1984) 288:1401–1404.
   PubMed Web of Science ®Google Scholar
• MANSON JE, COLDITZ GA, STAMOFER RJ et al.: A prospective study of obesity and risk of coronary heart disease in women. New Engl. J. Med. (1990) 322:882–889.
   PubMed Web of Science ®Google Scholar
• VAN GAAL L, VANSANT G, VAN CAMPENHOUT C, LEPOUTRE L, DE LEEUW I: Apolipoprotein concentrations in obese subjects with upper and lower body fat mass distribution. Int. j Obes. (1989) 13:255–263.
   PubMed Web of Science ®Google Scholar
• TERRY RB, WOOD PD, HASKEL WL et al.: Regional adiposity pattern in relation to lipids, lipoprotein cholesterol and lipoprotein subfraction in men. j. Endocnnol Metab. (1989) 68:191–199.
   PubMed Web of Science ®Google Scholar
• HARRIS PEEPLES L, CARPENTER JW, ISRAEL RG, BAKARAT HA: Alterations in low density lipoproteins in subjects with abdominal obesity. Metabolism (1989) 38:1029–1036.
   PubMedGoogle Scholar
• DESPRES JP: Abdominal obesity as important component of insulin-resistance syndrom. Nutrition (1993) 9:452–459.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, VERTOMMEN J, DE LEEUW IH: The in vitro oxidizability of lipoprotein particles in obese and non-obese subjects. A themsdrerosis (1998) 137(S):539–44.
   Google Scholar
• RENGSTROM J, NILSSON J, TORNALL P et al.: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet (1992) 339:1183–1186.
   PubMed Web of Science ®Google Scholar
• BEVENHOLM E PROUDLER A, TORNVALL P et al.: Insulin, intact and split proinsulin and coronary artery disease in young men. Circulation (1995) 92:1422–1429.
   PubMedGoogle Scholar
• HAFFNER S, MIETTINEN H: Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am. Med. (1997) 103:152–162.
   PubMedGoogle Scholar
• LAAKSO M, SARLUND H, SALONEN R etal.: Asymptomatic atherosclerosis and insulin resistance. Arterioscler. Thromb. (1991) 11:1068–1076.
   PubMed Web of Science ®Google Scholar
• LAAKSO M. Insulin resistance and coronary heart disease. Cun: Opin. Lipidol(1996) 7:217–226.
   PubMed Web of Science ®Google Scholar
• ALBERTI KG, ZIMMET PZ: Definition, diagnosis, and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. (1998) Diabet. Med. 15: 539–553.
   Google Scholar
• BLANKENHORN DH, KRAMSCH DM. Reversal of atherosis and sclerosis: the two components of atherosclerosis. Circulation (1989) 79:1–6.
   PubMed Web of Science ®Google Scholar
• BRENSIKE JE LEVY RI, KELSEY SF et al.: Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation (1984) 69:313–324.
   Google Scholar
• CASHIN-HEMPHILL L, MACK WJ, POGODA JM, SANMARCO ME, AZEN SP, BLANKENHORN DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-yr follow up study. JAMA (1990) 264:3013–3017.
   PubMed Web of Science ®Google Scholar
• SCRIP (2000) 2549:16.
   Google Scholar
• SCRIP (2000) 2510:10.
   Google Scholar
• SCRIP (2000) 2562:14.
   Google Scholar
• Drugs Today (2000) 36:4 and 187.
   Google Scholar
• SCRIP (2000) 2509:7.
   Google Scholar
• ZOPPO GJ: The role of platelets in ischaemic stroke. Neurology (1998) 51\(Suppl. 3):59–514
   Google Scholar
• •Precise overview containing basic science and clinical trials.
   Google Scholar
• KNIGHT CG, MORTON LE ONLEY JO et al.: Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc. Res. (1999) 41:450–457.
   Google Scholar
• SCHAFER Al: Antiplatelet therapy. Am. Med. (1996) 101:199–209.
   PubMedGoogle Scholar
• •Good overview of antiplatet drug mechanisms.
   Google Scholar
• FERGUSON JJ, WALY HM, WILSON JM: Fundamentals of coagulation and glycoproteinreceptor inhibition.Eur. Heart J. (1998) 19 (Suppl. D):D3–D9.
   Google Scholar
• ••Excellent description of the basis of thecoagulation mechanism.
   Google Scholar
• SCRIP (2000) 2563:21.
   Google Scholar
• SCRIP (2000) 2554:18.
   Google Scholar
• TARDIF JC: Insight into oxidative stress and atherosclerosis. Can. j. Cordial. (2000) 16(suppl. D):2D–4D.
   Google Scholar
• PATRONO C, COLLER B, DALEN JE et al.: Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest (1998) 114:470S–488S.
   Google Scholar
• •Good review of antiplatelet agents.
   Google Scholar
• AWTRY EH, LOSCALZO J: Aspirin. Circulation (2000) 101:1206–1218.
   PubMed Web of Science ®Google Scholar
• MCNEELY W, GOA KL: Triflusal. Drugs (1998) 55:823–833.
   PubMed Web of Science ®Google Scholar
• BEDNAR M: Stroke: antithrombin versus antiplatelet therapy. Expert Opin. Investig. Drugs (2000) 9(2):355–369.
   PubMedGoogle Scholar
• ••Excellent review with clinical implications.
   Google Scholar
• BECKER BF, HEIDL B, KUPATT C, ZAHLER S: Endothelial function and hemostasis. Z Kardiol (2000) 89:160–167.
   PubMedGoogle Scholar
• FRY JA, GRINES CL: Optimization of platelet therapy. Semin. Interverm Cordial (2000) 5:117–128.
   PubMedGoogle Scholar
• LEFKOVITS J, PLOW EF, TOPOL EJ: Platelet glycoprotein Ifip/IIIa receptors in cardiovascular medicine. New Eng. j Med. (1995) 332 (23):1553–1559.
   PubMedGoogle Scholar
• JORDAN R, MASCELLI MA: Pharmacological differentiation of GP lib/ IIIa inhibitors. Eur. Heart j Supplements (1999) 1 (Suppl. E):E3–E10.
   Google Scholar
• SCHROR K: Antiplatelet drugs. A comparative review. Drugs (1995) 50(1):7–28.
   Google Scholar
• KURODA M, ENDO A: Inhibition of in vitro cholesterol synthesis by fatty acids. Biochem. Phys. Acta (1996) 486(1):70–81.
   Google Scholar
• KAMISAKO T, GABAZZA EC, ISHIHARA T, ADACHI Y: Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. Castroenterol Hepatol (1999) 14:405–412.
   Google Scholar
• VEERKAMP JH, MAATMAN RG: Cytoplasmic fatty acid-binding proteins: their structure and genes. Frog. Lipid Res. (1995) 34:17–52.
   PubMed Web of Science ®Google Scholar
• BANASZAK L, WINTER N, XU Z, BERNLOHR DA, COWAN S, JONES TA: Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv. Prot. Chem. (1994) 45:89–131.
   PubMedGoogle Scholar
• RIBARIK COE N, BERNLOHR DA: Physiological properties and functions of intracellular fatty acid-binding proteins. Biochem. Biophys. Acta (1998) 1391:287–306.
   PubMedGoogle Scholar
• BERNLOHR DA, SIMPSON MA: Adipose tissue and lipid metabolism. In: Biochemistry of Lipids, Lipoproteins and Membranes. Vance DE, Nance JE (Eds.) Elsevier, New York, USA (1996):257–281.
   Google Scholar
• KANE CD, RIBARIK COE N, VANLANDINGHAM B, KRIEG P, BERNLOHR DA: Expression, purification and ligand binding analysis of recombinant keratinocyte lipid-binding protein (MAL- I), an intracellular lipd-binding protein found overexpressed in neoplastic skin cells. Biochemistry (1996) 35:2894–2900.
   PubMedGoogle Scholar
• BERNLOHR DA, RIBARIK COE N, SIMPSON M, HERTZEL AV: Regulation of gene expression in adipose cells by polyunsaturated fatty acids. Adv. Esp. Med. Biol. (1997) 422:145–156.
   PubMed Web of Science ®Google Scholar
• SIMPSON MA, LICATA WJ, RIBARIK COE N, BERNLOHR DA: Biochaemical and biophysical analysis of lipid binding proteins of adipocytes. Mal Cell. Biol. (1999) 192:33–40.
   Google Scholar
• RIBARIK COE N, SIMPSON MA, BERNLOHR DA: Targeted disruption of the adipcyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. _J. Lipid Res. (1999) 40:967–972.
   Google Scholar
• KANE CD, BERNLOHR DA: A simple assay for intracellular lipid-binding proteins using displacement of 1-anilinonaphthalene 8-sulfonic acid. Anal. Biochem. (1996) 233:197–204.
   PubMedGoogle Scholar
• GOTTLICHER M, WIDMARK E, LI Q, GUSTAFSSON JA: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA (1992) 89:4653–4657.
   PubMed Web of Science ®Google Scholar
• KELLER H, DREYER C, MEDIN J, MAHFOUDI A, OZATO K, WAHLI W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid heterodimers. Proc. Natl. Acad. Sri. USA (1993) 90:2160–2164.
   PubMed Web of Science ®Google Scholar
• KAIKAUS RIVI, CHAN WK, ORTIZ-DE-MOTELLANO PR, BASS NM: Mechanisms of regulation of liver fatty acid-binding protein. Mal Cell. Biochem. (1993) 123:93–100.
   PubMedGoogle Scholar
• ISSEMANN I, PRINCE RA, TUGWOOD JD, GREEN S: The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. j Mal Endocrynol (1993) 11:37–47.
   PubMed Web of Science ®Google Scholar
• STEINBRECHER UP, ZHANG H, LOUGHEED M: Role of oxidatively modified LDL in atherosclerosis. Free Radic. Biol. Med. (1990) 9:155–168.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISON WO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPAR 7).j Biol Chem. (1995) 270:12953–12956
   PubMed Web of Science ®Google Scholar
• GEY KF. Optimum plasma levels of antioxidant micronutrients. Ten-year retrospective on the antioxidant hypothesis of arteriosclerosis. Bibl. Num. Dieta (1994) 51:84–89.
   Google Scholar
• GRYGLEWSKI RJ, CHLOPICKI S, SWIES J, NIEZABITOWSKI P: Prostacyclin, nitric oxide, and atherosclerosis. Ann. NY Acad. Sci. (1995) 17 (748):194–206.
   Google Scholar
• GRYGLEWSKI RJ, KORBUT R, OCETKIEWICZ A, STACHURA J: In vivo method for quantitation for anti-platelet potency of drugs. Naurtyri. Schmiedebergs Arch. Pharmacol (1978) 302 (1): 25–30.
   PubMedGoogle Scholar
• KETTNER C, MERSINGER L, KNABB R: The selective inhibition of thrombin by peptides of boroarginine. I Biol. Chem. (1990) 265 (30):18289–97.
   Google Scholar
• UMETSU T, SANAI K: Effect of I-methyl-2-mercapto 5 (3 pyridyfidmidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb. Haemost. (1978) 39 (1):74–83.
   PubMedGoogle Scholar
• TAPPARELLI C, METTERNICH R, EHRHARDT C et al: In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. _J. Biol. Chem. (1993) 268 (7):4734–41
   PubMedGoogle Scholar
• THEBAUD B, SAIZOU C, FARNOUX C, HARTMAN JF, MERCIER JC. Dypiramidole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia. Intens. Care Med. (1999) 25:300–303.
   Google Scholar
• SLY MK, EBERHARDT RC, PRAGER MD: Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors. Shock (1997) 8:115–118.
   PubMedGoogle Scholar
• YU SM, TSAI SY, KUO SC, OU JT: Inhibition of platelet function by A02131-I, a novel inhibitor of cGMP specific phosphodiesterase, in vitro and in vivo. Blood(1996) 87:3758–3767.
   PubMed Web of Science ®Google Scholar
• ZUCKER MB: Platelet aggregation measured by the photometric method. Methods Ertzymol. (1989) 169:117–33.
   PubMedGoogle Scholar
• REYERS I, MUSSONI L, DONATI MB, DE GAETANO G: Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb. Res. (1980) 18(5):669–674.
   PubMedGoogle Scholar
• VALENTIN JP, VIEU S, BERTOLINO F, FAURE P, JOHN GW: Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits. I Pharmacol Exp. Ther. (1997) 280 (2):761–769.
   PubMed Web of Science ®Google Scholar
• CIRINO G, CICALA C, MANCUSO F, BAYDOUN AR, WALLACE JL: Flurbinitroxybutylester: a novel anti-inflammatory drug has enhanced antithrombotic activity. Thromb. Res. (1995) 79 (1):73–81.
   PubMedGoogle Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• MAAS INVESTIGATORS. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet (1994) 344:633–638.
   PubMed Web of Science ®Google Scholar
• BRADFORD RH, SHEAR CL, CHREMOS AN etal.: Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse profile in 8245 patients with moderate hypercholesterolemia. Arch. Int. Med. (1991) 151:43–49.
   Google Scholar
• MANNINEN V, ELO MO, FRICK MH et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 260:641–651.
   PubMed Web of Science ®Google Scholar
• FRICK MH, ELO MO, HAAPA K et al.: Helsinki Heart Study: primary-intervention trial with gemfibrozil in middle-aged men with dislipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disese. New Engl. J. Med. (1987) 317:1237–1245.
   Google Scholar
• BARNDT R, BLANKENHORN DH, CRAWFORD DW, BROOKS SH: Regression and progression of early femoral atherosclerosis in treated hyperlipidaemic patients. Ann. Intern. Med. (1977) 86:139–146.
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trialsof antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ(1994) 308 (6921):81–106.
   Google Scholar
• Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New EngL J. Med. (1994) 330:956–961.
   PubMedGoogle Scholar
• CAPRIE STEERING COMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMedGoogle Scholar
• PLATELET RECEPTOR INHIBITION IN ISCHAEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New EngL Med. (1998) 338:1498–1505.
   PubMedGoogle Scholar